Dr. Aderhold hat darauf geantwortet

Sharfstein S. S.(2005): Big Pharma and American Psychiatry: The Good, the Bad and the
Ugly, in: Psychiatric News, 19. August, p. 3
Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH.(2007) Impaired glucose tolerance in
first-episode drug-naïve patients with schizophrenia. Diabet Med. 24(5):481-5.
Staller, J.A. (2007): “Psychopharmacologic treatment of aggressive preschoolers: a chart
review.” Prog Neuropsychopharmacol Biol Psychiatry. 31(1):131-5.
Steinert, T.(2008): Neuroleptika der 2. Generation nach CATIE – ein Glaubenskrieg? Sozialpsychiatrische
Informationen 2: 21-24
Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom
MC, Stricker BH. (2004): Antipsychotics and the risk of sudden cardiac death. Arch. Intern.
Med. 164(12):1293-7.
Studdert, D. M., Mello, M. M., & Brennan, T. A. (2004). Financial conflicts of interest in physicians’
relationships with the pharmaceutical industry–self regulation in the shadow of federal
prosecution. New England Journal of Medicine 351(18): 1891–1900.
Thornley B, Adams CE, Awad G.(2000): Chlorpromazine versus placebo for schizophrenia.
Cochrane Database Syst Rev.(2):CD000284.
Torrey EF (2002) The going rate on shrinks. The American Prospect, volume 13, issue 13,
2002. www.prospect.org.
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R.(2008): Selective publication of
antidepressant trials and its influence on apparent efficacy. N Engl J Med. 358(3):252-60
Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA.(2005):
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J
Med. 353(22):2335-41.
Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA.(2005):
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J
Med. 353(22):2335-41.
Wazana, A. (2000): Physicians and the pharmaceutical industry: Is a gift ever just a gift?
Journal American Medical Association, 283(3), 373–380.
WHO (2008): Global strategy and plan of action on public health, innovation and intellctual
propertry. Resolution WHA 61.21. Element 1.3
Witchel HJ, Hancox JC, Nutt DJ.(2003): Psychotropic drugs, cardiac arrhythmia, and sudden
death. J Clin Psychopharmacol. 23(1):58-77.
Zarate CA Jr, Patel J.(2001): Sudden cardiac death and antipsychotic drugs: do we know
enough? Arch Gen Psychiatry. 58(12):1168-71.
18